Reference:
Mead, M. N., Seneff, S., Wolfinger, R., Rose, J., Denhaerynck, K., Kirsch, S., & McCullough, P. A. (2024). COVID-19 mRNA vaccines: Lessons learned from the registrational trials and global vaccination campaign. Cureus, 16(1), e52876. https://doi.org/10.7759/cureus.52876
Summary:
The article critically examines the safety and efficacy of COVID-19 mRNA vaccines, highlighting significant concerns regarding trial methodologies and data reporting. Early trials suggested high efficacy; however, subsequent analyses revealed substantial adverse events (AEs), including serious health complications. The authors argue that these vaccines did not undergo adequate safety evaluations and raise questions about the regulatory processes that allowed their rapid approval. They emphasise the need for transparency in reporting AEs and the importance of long-term safety monitoring. The review calls for a reevaluation of the risk-benefit balance associated with mRNA vaccines, particularly in children, citing an urgent need for more thorough safety studies before further use. Ultimately, the authors advocate for a moratorium on mRNA vaccines until all safety concerns are resolved, underscoring the potential for significant harm and highlighting the importance of informed consent in vaccination programmes.